Akumentis Healthcare Ltd
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)
Switglim MV 1mg/500mg/0.3mg Tablet is a combination of three antidiabetic medicines used to treat type 2 diabetes mellitus in adults.
Tablet
Switglim MV 1mg/500mg/0.3mg Tablet belongs to a category of medicines known as anti-diabetic drugs. It is a combination of medicines used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels in people with diabetes.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Switglim MV 1mg/500mg/0.3mg Tablet is to be taken empty stomach.
No common side effects listed.
It is unsafe to consume alcohol with Switglim MV 1mg/500mg/0.3mg Tablet.
Switglim MV 1mg/500mg/0.3mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Switglim MV 1mg/500mg/0.3mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Switglim MV 1mg/500mg/0.3mg Tablet is a combination of three antidiabetic medicines:
Take it with food to lower your chance of having an upset stomach. It can cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines Carry a sugar source with you for immediate relief. Your doctor may check your liver function regularly. Inform your doctor if you develop symptoms such as abdominal pain, loss of appetite, or yellowing of the eyes or skin (jaundice).
Switglim MV 1mg/500mg/0.3mg Tablet contains Glimepiride, Metformin, and Voglibose. This medication is prescribed for the treatment of type 2 diabetes mellitus (DM). It helps manage blood glucose levels in adults when taken with a balanced diet and regular physical activity. Glimepiride increases insulin release from the pancreas. Metformin lowers glucose production in the liver and improves insulin sensitivity. Voglibose is an alpha-glucosidase inhibitor that reduces postprandial (after meals) glucose levels.
Common side effects associated with Switglim MV 1mg/500mg/0.3mg Tablet include hypoglycemia (low blood sugar level), nausea, diarrhea, altered taste, flatulence, stomach pain, headache, skin rash and respiratory tract infection.
Switglim MV 1mg/500mg/0.3mg Tablet is contraindicated for patients with known allergy to any of the ingredients or excipients, as well as those with moderate to severe kidney disease and inflammatory bowel disease, colonic ulcerations, and underlying metabolic acidosis including diabetic ketoacidosis.
No, consuming alcohol with Switglim MV 1mg/500mg/0.3mg Tablet is not recommended as it can lower blood sugar levels (hypoglycemia) and increase the risk of lactic acidosis.
Yes, Switglim MV 1mg/500mg/0.3mg Tablet can lead to hypoglycemia (low blood sugar level). Symptoms include nausea, headache, irritability, hunger, sweating, dizziness, fast heart rate, and feeling anxious or shaky. It is more likely to occur if you miss meals, consume alcohol, engage in excessive physical activity, or take other diabetes medications concurrently.
Store Switglim MV 1mg/500mg/0.3mg Tablet in its original packaging, tightly sealed. Follow the storage instructions provided on the package label. Dispose of unused medication safely and ensure that it is not accessed by children, pets, or other individuals.